Updated warnings for Respiratory Syncytial Virus vaccines Arexvy and Abrysvo

News Healthcare & Pharma Guidance

Date: 19th May, 2025 Source: Therapeutic Goods Administration (TGA) Country: Australia Original Source

Brief

On March 24, 2025, the Therapeutic Goods Administration (TGA) issued an update regarding updated warnings for Respiratory Syncytial Virus vaccines Arexvy and Abrysvo. The TGA informed health professionals about the low risk of Guillain-Barre syndrome (GBS) following vaccination with these products, emphasizing the importance of monitoring symptoms to ensure correct diagnosis and timely treatment.

This content is restricted.

Highlights content goes here...

This content is restricted.

Therapeutic Goods Administration (TGA)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Updated warnings for Respiratory Syncytial Virus vaccines Arexvy and Abrysvo

Brief

Therapeutic Goods Administration (TGA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Updated warnings for Respiratory Syncytial Virus vaccines Arexvy and Abrysvo

Brief

Therapeutic Goods Administration (TGA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.